@article{3840f44e0d264d4690ee127b157f304a,
title = "A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern",
abstract = "Numerous vaccines have been developed to address the current COVID-19 pandemic, but safety, cross-neutralizing efficacy, and long-term protectivity of currently approved vaccines are still important issues. In this study, we developed a subunit vaccine, ASD254, by using a nanoparticle vaccine platform to encapsulate the SARS-CoV-2 spike receptor-binding domain (RBD) protein. As compared with the aluminum-adjuvant RBD vaccine, ASD254 induced higher titers of RBD-specific antibodies and generated 10- to 30-fold more neutralizing antibodies. Mice vaccinated with ASD254 showed protective immune responses against SARS-CoV-2 challenge, with undetectable infectious viral loads and reduced typical lesions in lung. Besides, neutralizing antibodies in vaccinated mice lasted for at least one year and were effective against various SARS-CoV-2 variants of concern, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Furthermore, particle size, polydispersity index, and zeta-potential of ASD254 remained stable after 8-month storage at 4°C. Thus, ASD254 is a promising nanoparticle vaccine with good immunogenicity and stability to be developed as an effective vaccine option in controlling upcoming waves of COVID-19.",
author = "Lee, {I. Jung} and Lan, {Yu Hua} and Wu, {Ping Yi} and Wu, {Yan Wei} and Chen, {Yu Hung} and Tseng, {Sheng Che} and Kuo, {Tzu Jiun} and Sun, {Cheng Pu} and Jan, {Jia Tsrong} and Ma, {Hsiu Hua} and Liao, {Chun Che} and Liang, {Jian Jong} and Ko, {Hui Ying} and Chang, {Chih Shin} and Liu, {Wen Chun} and Ko, {Yi An} and Chen, {Yen Hui} and Sie, {Zong Lin} and Tsung, {Szu I.} and Lin, {Yi Ling} and Wang, {I. Hsuan} and Tao, {Mi Hua}",
note = "Funding Information: This work was supported by Academia Sinica, Taiwan grant AS-KPQ-110-EIMD and AS-KPQ-111-KNT. We thank ASCENDO Biotechnology, Inc., Taipei, for providing the ASD25x platform; the Biosafety Level 3 Facility in the Genomic Research Center, Academia Sinica (AS-CFII-108-101) for SARS-CoV-2 animal challenge experiments; the Biosafety Level 3 Facility in the Institute of Biomedical Sciences, Academia Sinica (AS-CFII-108-102) for authentic SARS-CoV-2 neutralization experiments; the AAV Core Facility in the Institute of Biomedical Sciences, Academia Sinica (AS-CFII109-103) for providing the AAV/hACE2 animal model; the Flow Cytometry Core Facility in the Institute of Biomedical Sciences, Academia Sinica (AS-CFII108-113) for supplying flow cytometry instrumentation; the DNA Sequencing Core Facility of the Institute of Biomedical Sciences, Academia Sinica (AS-CFII-111-211) for sequencing support; the Inflammation Core Facility of the Institute of Biomedical Sciences, Academia Sinica for multiplex cytokine analysis; the Pathology Core Facility of the Institute of Biomedical Sciences, Academia Sinica for tissue embedding and pathological service; the Infectious Disease Core Facility in the Biomedical Translation Research Center, Academia Sinica, for technical support; the National RNAi Core Facility in the Biomedical Translation Research Center, Academia Sinica, for providing the 293T-hACE2 cell line and SARS-CoV-2 pseudovirus; and the Taiwan CDC for providing the SARS-CoV-2 virus (hCoV-19/Taiwan/4/2020). Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd.",
year = "2023",
doi = "10.1080/22221751.2022.2149353",
language = "English",
volume = "12",
journal = "Emerging Microbes and Infections",
issn = "2222-1751",
publisher = "Nature Publishing Group",
number = "1",
}